Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05125029 · ClinicalTrials.gov registry record · Phase 4
Botulinum Toxin in Raynaud's Phenomenon
A Phase 4 study of Raynaud Phenomenon, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT05125029 is a Phase 4 study of Raynaud Phenomenon that is actively recruiting participants, run by Emory University. The registered enrollment target is 36 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05125029, a Phase 4 study of Raynaud Phenomenon, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Raynaud's Phenomenon (RP) is the most common vasospastic disorder encountered by hand surgeons with an estimated prevalence of 5% in the general population. It's manifestations are broad, and can range from minor to severe. Sometimes it can be refractory to treatments. The goal of this study is to evaluate the efficacy of Botulinum toxin (BT) in the treatment of treatment refractory RP by objective and subjective measures.
Conditions Studied
Interventions
- DRUG Botulinum toxin
Study Locations (1)
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-02-10 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05125029
The ClinicalTrials.gov registry entry for NCT05125029 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Raynaud Phenomenon appearing as the primary indexed condition, and to 1 intervention - of which Botulinum toxin is the first listed.
NCT05125029 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05125029 about?
NCT05125029 is a clinical study titled "Botulinum Toxin in Raynaud's Phenomenon". Raynaud's Phenomenon (RP) is the most common vasospastic disorder encountered by hand surgeons with an estimated prevalence of 5% in the general population. It's manifestations are broad, and can range from minor to severe. Sometimes it can be refractory to treatments. The goal of this study is to e...
What is the current status of trial NCT05125029?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2022-02-10. Estimated completion is 2025-12.
What conditions does trial NCT05125029 study?
This clinical trial studies the following conditions: Raynaud Phenomenon.
What interventions are being tested in trial NCT05125029?
The interventions under investigation include: Botulinum toxin (DRUG).
Who is sponsoring clinical trial NCT05125029?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05125029 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.